Tech Company Financing Transactions
Vergent Bioscience Funding Round
Vergent Bioscience, based in Minneapolis, received $8.7 million in investment from Spring Mountain Capital and private investors.
Transaction Overview
Company Name
Announced On
6/13/2018
Transaction Type
Venture Equity
Amount
$8,700,000
Round
Series A
Investors
Spring Mountain Capital (Lead Investor) (Raymond Wong)
Proceeds Purpose
Vergent is developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5810 W 78th St. 222
Minneapolis, MN 55439
USA
Minneapolis, MN 55439
USA
Phone
Undisclosed
Website
Email Address
Overview
Vergent is a biotechnology company developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. Surgery is often the first-line treatment for solid tumors and the prognosis of a procedure is highly correlated with achieving complete tumor removal.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Santini
Browse more venture capital transactions:
Prev: 6/13/2018: Heatworks venture capital transaction
Next: 6/14/2018: Tropic Biosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs